Morrison Foerster Named Firm of the Year in Four Practice Areas by China Business Law Journal 2022 –

Morrison Foerster has been named as a Firm of the Year in the four practice areas listed below for China Business Law Journal’s 2022 China Business Law Awards.

  • Anti-bribery & anti-corruption 反贿赂及反腐败
  • Fintech & blockchain 金融科技及区块链
  • Healthcare, pharma & life sciences 医疗、制药及生命科学
  • Technology & telecoms 信息科技及电信

The China Business Law Awards are based on hundreds of nominations received from China-focused corporate counsel and legal professionals around the world. In determining the winners, the nominations (and the justifications provided for each nomination) were considered carefully in combination with other factors, such as each firm’s landmark deals, cases, and other notable achievements over the past year. You can view the list of winners by visiting the website.

Morrison Foerster was also recently shortlisted in the International Law Firm of the Year, IP Law Firm of the Year (International), and Private Equity Law Firm of the Year – International categories for the SSQ ALB China Law Awards 2022. During the past year, Morrison Foerster handled a number of significant transactional and contentious matters for our clients, including, among many others:

  • A leading institutional investor and long-time investor in Grab Holdings in connection with Grab’s proposed merger with SPAC Altimeter Growth Corp. The transaction is expected to be the largest-ever U.S. equity offering by a Southeast Asian company, valuing Grab at US$39.6 billion.
  • Silver Crest Acquisition Corporation, a publicly traded SPAC, in connection with its US$1.69 billion business combination with TH International Limited, a master franchisee and operator of Tim Hortons coffee shops in China.
  • Sino-Ocean Capital, one of China’s leading alternative asset managers with more than US$19 billion in AUM, in the formation of a US$1.4 billion core office fund that will invest in A-grade office projects in the core business districts of Tier 1 cities in China. Morrison Foerster also advised Sino-Ocean Capital on the formation of a US$600 million China real estate special situations fund, which is one of the first U.S.-dollar-denominated special situations funds focusing on residential special situation investments in core cities in China.
  • Sailing Capital in the formation of its flagship private equity fund II, with a target size of US$1 billion, and the fund’s employee co-investment program.
  • Ally Bridge Group in connection with numerous investments in various life sciences companies, including Sonoma Biotherapeutics, Mainstay Medical Holdings plc, Syapse, Vida Health, Inc., and Rapid Micro Biosystems, Inc.
  • Macquarie Asset Management in its investment in Unified Industrial Group, a real estate investment and development platform focused on the industrial and logistics sector in Japan and China.
  • Ascendent Capital Partners in its disposal of Etern Group Ltd., which indirectly holds 98% of the equity interest in a general hospital in Suzhou, to Hygeia, a Hong Kong-listed healthcare company, for a total consideration of RMB1,734,600,000 (approximately US$267 million).
  • Alpha Fintech, a next-gen payments technology company, in its acquisition by PPRO, a leading digital payments infrastructure provider.
  • A startup blockchain company in its de-SPAC transaction with an estimated value of US$1 billion.
  • A HKEX-listed global technology conglomerate holding company that provides fintech services including mobile payments, wealth management, loans, and securities trading to users around the globe in various matters.
  • A U.S.-based multinational company in a corruption and money laundering investigation by the U.S. Department of Justice and U.S. Securities and Exchange Commission relating to an alleged corruption scheme that took place across China and Europe.
  • A leading Fortune 100 life sciences company in dozens of fraud and bribery investigations in connection with its pharmaceutical business in China.
  • A Europe-listed global medical technology company in a highly sensitive internal investigation involving corruption and other compliance issues in China, Taiwan, and Hong Kong.
Spread the love

Leave a Reply

Your email address will not be published.